Thirty-eight healthy female volunteers used a luteinizing hormone-releasing hormone agonist (LHRH-A) for inhibition of ovulation and contraception for 1 to 4 months.The potent agonist LHRH-A,(D-Ala^6,des-Gly-NH2^10)-L...Thirty-eight healthy female volunteers used a luteinizing hormone-releasing hormone agonist (LHRH-A) for inhibition of ovulation and contraception for 1 to 4 months.The potent agonist LHRH-A,(D-Ala^6,des-Gly-NH2^10)-LHRH ethylamide was administered intranasally in a daily dose of 0.5mg tp 10 women or 1.0mg to 28 women for 21 (Intermittent treatment group) or 30 days (Continuous treatment group).The treatment inhibited ovulation in all women during the 70 monthes of treatment.No pregnancies occurred during the treatment period in which no additional contraceptives were used.More significent menstruation disorders were observed in the continuous treatment group than that in the intermittent treatment group.There were no serious side effects.Ovulation occurred again promptly after the cessation of treatment even in women with amenorrhea during the period of treatment.The results suggest that the most appropriate dosage regimen for contraception by inhibition of ovulation in women was 0.5-1.0mg of LHRH-A/per day for 21 days.展开更多
OBJECTIVE To evaluate the results and complications associated with nasopharyngeal carcinoma （NPC） treated with combined external-beam radiotherapy （EBR） and intracavitary brachytherapy （IB） using a new-type app...OBJECTIVE To evaluate the results and complications associated with nasopharyngeal carcinoma （NPC） treated with combined external-beam radiotherapy （EBR） and intracavitary brachytherapy （IB） using a new-type applicator. METHODS Eighty patients with untreated NPC were divided into two groups based on therapy methods. An experimental group was treated with EBR plus IB and a control group was treated only with EBR. IB was given to the patients of the experimental group when the external radiotherapy dose amounted to more than 60～65 Gy. The total dose of IB was 6～20 Gy and the total dose of EBR of the control group was 70～75 Gy. RESULTS Follow-up was conducted for 97.5% of the patients with re- suits as follows： the overall response rates （ORR） for the experimental and the control groups were 92.5% and 75.3% respectively （P〈0.05）; the 3 and 5-year survival rates for the experimental group were 87.5% and 74.2% and for the control group, 65.0% and 55.6% （P〈0.05）; for the experimental group, the 3 and 5-year disease-free survival rates were 72.5% and 64.5% and for the control group, 60.0% and 52.8% （P〉0.05）.Some complications following radiotherapy showed a significant difference. CONCLUSION External irradiation plus intracavitary brachytherapy using a new-type applicator may improve the ORR and survival rates, reduce radiation complications and increase the quality of life. 展开更多
文摘Thirty-eight healthy female volunteers used a luteinizing hormone-releasing hormone agonist (LHRH-A) for inhibition of ovulation and contraception for 1 to 4 months.The potent agonist LHRH-A,(D-Ala^6,des-Gly-NH2^10)-LHRH ethylamide was administered intranasally in a daily dose of 0.5mg tp 10 women or 1.0mg to 28 women for 21 (Intermittent treatment group) or 30 days (Continuous treatment group).The treatment inhibited ovulation in all women during the 70 monthes of treatment.No pregnancies occurred during the treatment period in which no additional contraceptives were used.More significent menstruation disorders were observed in the continuous treatment group than that in the intermittent treatment group.There were no serious side effects.Ovulation occurred again promptly after the cessation of treatment even in women with amenorrhea during the period of treatment.The results suggest that the most appropriate dosage regimen for contraception by inhibition of ovulation in women was 0.5-1.0mg of LHRH-A/per day for 21 days.
文摘OBJECTIVE To evaluate the results and complications associated with nasopharyngeal carcinoma （NPC） treated with combined external-beam radiotherapy （EBR） and intracavitary brachytherapy （IB） using a new-type applicator. METHODS Eighty patients with untreated NPC were divided into two groups based on therapy methods. An experimental group was treated with EBR plus IB and a control group was treated only with EBR. IB was given to the patients of the experimental group when the external radiotherapy dose amounted to more than 60～65 Gy. The total dose of IB was 6～20 Gy and the total dose of EBR of the control group was 70～75 Gy. RESULTS Follow-up was conducted for 97.5% of the patients with re- suits as follows： the overall response rates （ORR） for the experimental and the control groups were 92.5% and 75.3% respectively （P〈0.05）; the 3 and 5-year survival rates for the experimental group were 87.5% and 74.2% and for the control group, 65.0% and 55.6% （P〈0.05）; for the experimental group, the 3 and 5-year disease-free survival rates were 72.5% and 64.5% and for the control group, 60.0% and 52.8% （P〉0.05）.Some complications following radiotherapy showed a significant difference. CONCLUSION External irradiation plus intracavitary brachytherapy using a new-type applicator may improve the ORR and survival rates, reduce radiation complications and increase the quality of life.
